The data are early both in terms of trial stage and time point, but Roche Holding AG’s newly acquired CT-996 looks like it might be the most effective obesity pill yet. The GLP-1 agonist, which Roche got when it bought Carmot Therapeutics Inc. for $2.7bn in December, looks more effective even than Viking Therapeutics, Inc.’s VK2735 – though this asset is more advanced.
Roche Could Have The Best Obesity Pill
That is, if very early data in a handful of patients are borne out in later, larger studies.
More from Business
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
More from Scrip
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.